Previous studies have shown that obtaining complete hematologic remission (CR) in multiple myeloma is an important predictor of PFS and OS. This applies both to autologous and allogeneic transplantation. However, the importance of CR obtained before vs after second transplant or following allogeneic vs autologous transplantation is not clear. We investigated the role of CR analyzing data from the EBMT-NMAM2000 interventional prospective study comparing tandem autologous/reduced intensity conditioning allogeneic transplantation (auto/RICallo) to autologous transplantation-single or double (auto/auto). Allocation to treatment was performed according to availability of a matched sibling donor. Cox regression and multi-state models were applied. The long-term probability of survival in CR was superior in auto/RICallo, both comparing groups according to treatment allocated at start (28.8 vs 11.4% at 60 months, P = 0.0004) and according to actual administration of second transplant (25.6 vs 9.6% at 60 months, P = 0.008). CR achieved before the second transplant was predictive for PFS (hazard ratio (HR) = 0.44, P = 0.003) and OS (HR 0.51, P = 0.047) irrespective of the type of second transplant. CR achieved after auto/RICallo was more beneficial for PFS (HR = 0.53, P = 0.027) than CR after auto/auto (HR = 0.81, P = 0.390), indicating a better durability of CR obtained after an allotransplant procedure.
INTRODUCTION
Previous studies have shown that obtaining a complete hematologic remission (CR) in multiple myeloma is an important predictor for PFS and OS. In the transplant setting, it applies to CR obtained both with autologous [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] and allogeneic transplantation. 12 However, the importance of the CR status before and after the second transplant (hematopoietic SCT (HSCT)), and whether it differs according to type of second HSCT remains unclear. The prospective NMAM2000 trial compared autologous followed by reduced intensity conditioning allogeneic (auto/RICallo) HSCT with autologous-single (auto) or tandem (auto/auto)-HSCT in newly diagnosed patients with multiple myeloma. 13 The primary endpoint was PFS. As recently confirmed in the update of the study after a median follow-up of 96 months, 14 PFS was superior in the auto/RICallo arm as compared with the auto arm, as a result of lower progression/relapse rates. Superior long-term OS and higher CR rates using auto/RICallo were also observed. In the present study, we have analyzed and compared the impact on PFS and OS of the CR status at different steps (before or after second transplant) of the auto/RICallo or auto/auto protocol.
We have used both Cox regression and multi-state models [15] [16] [17] to properly take into account time-dependence of CR achievement (as well as of administration of second transplant), 4, 11 showing also the probability of long-term survival in CR with the two transplant approaches.
SUBJECTS AND METHODS Subjects
The NMAM2000 study enrolled 357 patients from February 2001 to January 2005. 13 Patients were included if at least in stable disease after induction and prior to first HSCT, after giving informed consent. Patients with an HLA-identical sibling donor were allocated to the auto/RICallo arm, the others were allocated to single or tandem auto according to physician's and patient's decisions. Patients' characteristics were previously described in detail. 13 Characteristics at inclusion were evenly distributed with the exception of age, which was slightly higher in the auto arm (median 57 vs 54 years in the auto/RICallo arm). The main analysis 13, 14 was made on outcomes measured since first HSCT and on an intention-to-treat basis. A second analysis compared outcomes after second HSCT according to protocol. We followed a similar approach in the current analysis. To use multi-state models focusing on the role of CR (defined according to EBMT criteria) 18 and of double auto or RICallo second HSCT, we considered 346 patients, 242 enrolled in the auto arm and 104 in the auto/RICallo arm, excluding 5 patients because of missing information on the date of achievement of CR and 6 patients who received second HSCT not according to protocol. Sensitivity analyses showed that results are not affected when other approaches are chosen to deal with protocol violations. Patient flows are reported in Figures 1a and b . Ninety-one patients received RICallo and 102 patients received second autologous HSCT according to protocol, and were included in the analyses of outcomes after second transplant.
Statistical methods
Two multi-state models [15] [16] [17] with six states and nine transitions were used to investigate the interplay between CR and progression/relapse or death. A brief introduction to multi-state models is provided as Supplementary information. The schema of the two models, with patient numbers and flows are represented in Figures 1a and b. All patients started in the state 'First transplant'. Death or progression (first model, PFS) or Death (second model, OS) were the final states; in addition, patients could enter one or two of four intermediate states characterized by the occurrence of second HSCT and of CR, taking into account the sequence of these two events. We used the non-parametric Aalen-Johansen estimator for the transition hazards and computed accordingly the transition probabilities and their standard errors. [19] [20] [21] Differences between the curves with point-wise 95% confidence intervals and significance tests at 5 and 8 years were developed in analogy to Klein et al., 22 based on the untransformed quantities of interest.
Left-truncated Cox models 23 were used to assess the impact of CR on the hazard of PFS and OS after second HSCT (Tables 1 and 2 ). CR achieved after second HSCT was included as a time-dependent covariate. The models were stratified by arm to avoid violation of the proportional hazard assumption (see Supplementary information).
All analyses were performed using R version 2.14.1, (R is a product of The R Foundation for Statistical Computing (http://www.r-project.org/)) using the package 'mstate' 21 for the multi-state models.
RESULTS

Survival in first CR
In our study, patients in the auto/RICallo arm had a higher total CR rate than patients in the auto arm (51% vs 41% at 60 months, Abbreviations: HR = hazard ratio; trx = transplant. The treatment arm showed a strong non-constant effect and was thus included as a stratification factor.
CR before and after transplant in MM S Iacobelli et al respectively 13 ). The probability of surviving without myeloma depends on this component and on the subsequent probability of relapse or death, but cannot be derived by separate estimation of the probabilities of CR achievement and relapse-free survival. We thus used a multi-state approach to compute the probability of this endpoint. Figure 2a illustrates the curves from study entry according to the assigned HSCT strategy. To assess significance, Figure 2b shows the difference between the two curves, with its confidence intervals. The latter are all above zero from time equal to 24 months, meaning that since that time auto/RICallo arm was significantly superior to the auto arm at 5% level. The probability of being alive in CR at 60 months was 28.8% and 11.4%, respectively, in auto/RICallo and auto arm (P = 0.0004) and remained significantly different in the long-term follow-up (21.3 vs 10.1% at 96 months, P = 0.015).
To compare the outcome according to type of second HSCT, we computed predictions from 4 months, as the landmark time closest to the median time to second transplant in auto/auto (4.28 months) and auto/RICallo arm (4.21 months). Importantly, conclusions hold also with different landmark times. Results are shown in Figures 3a and c, respectively, for patients not yet in CR and for patients in CR at 4 months. Figure 3b again illustrates the difference between the curves displayed in Figure 3a , with 95% confidence intervals for each point estimate. Again, this band is almost continuously above 0 after 24 months, indicating a strong trend of global significance of the advantage of auto/RICallo as compared with auto/auto. The probability of being alive and in CR was 25.6% vs 9.6% (P = 0.008) at 60 months and 18.0% vs 9.2% (P = 0.120) at 96 months for patients not in CR who received auto/ RICallo and auto/auto, respectively. Impact of CR on PFS and OS from second HSCT The impact of CR achievement before and after second HSCT was investigated in the subpopulation of patients who received second transplant according to protocol. The impact on the hazard of failure was analyzed using Cox regression, and actual probabilities were illustrated by curves obtained by the multistate model. Table 1 reports the Cox models where the effect of CR was evaluated under the assumption of being the same for both types of second HSCT. For PFS and OS, CR was beneficial both when achieved before (hazard ratio, HR = 0.45, P = 0.003 for PFS; HR = 0.51, P = 0.047 for OS) and after second HSCT (HR = 0.68, P = 0.040 for PFS; HR = 0.67, P = 0.079 for OS). We then investigated the effects of CR achievement according to second transplant (Table 2 ). Being in CR as compared with not being in CR at second HSCT was beneficial for both PFS and OS regardless of HSCT arm (HR = 0.44, P = 0.003 for PFS; HR = 0.51, P = 0.047 for OS). However, (a) Probability of survival in first CR estimated at study entry according to treatment allocation. Black = Auto arm, Grey = auto/RICallo arm. The curves increase as patients enter the CR status, and decrease as they relapse or die. (b) Difference between the two curves, with point-wise 95% confidence intervals (CI). When the 95% CI is above the horizontal line at 0, the difference is statistically significant at the 5% level. Abbreviations: HR = hazard ratio; trx = transplant; RICallo = reduced intensity conditioning allogeneic transplantation. The treatment arm showed a strong non-constant effect and was thus included as a stratification factor.
Time since first auto (months)
Probability of survival in first CR predicted at 4 months for patients not in CR achieving CR after RICallo was more important for PFS than achieving CR after second auto (CR after auto/auto: HR = 0.81, P = 0.390; CR after auto/RICallo: HR = 0.53, P = 0.027), while it was not significantly different for OS. Multi-state model: The impact of CR achievement after second HSCT on the probability of PFS is illustrated in Figures 4a and b . The figures illustrate the dynamic prediction of the probability that the patient will be alive and progression-free at 60 months (Figure 4a) or 96 months (Figure 4b) . The horizontal axis reports the time when the prediction is made (limited to the period from 3 to 15 months). The auto/RICallo curves are above the auto/auto curves, consistent with all analyses previously reported 16 that indicated superiority of the first regimen. In particular, an auto/ RICallo patient with CR achieved during the first year after RICallo has a probability equal to 31% or higher of being still alive and in CR at 8 years, compared with less than 18% of an auto/auto patient (Figure 4b ). The impact of achieving CR is represented by the distance between the curve represented by a dotted line (no CR after second HSCT) and the curve represented by a solid line (CR achieved after second HSCT). The advantage of obtaining CR after HSCT is higher in auto/RICallo (for example, at 9 months, 11% compared with 5%), confirming the finding of the Cox model of a stronger impact of CR on PFS when obtained with RICallo as compared with second auto.
Figures 4c and d illustrate the impact of CR achievement after second transplant on OS probability (the interpretation of the graphs is the same as in Figures 4a and b) . Given the response status, the auto/RICallo curves are again superior to the auto/auto curves, 16 and the CR status is associated with improved OS compared to no CR. However, consistently with the Cox analysis that did not detect significant differences, the impact of CR according to the type of second HSCT cannot be determined. Figure 4c suggests that CR obtained after auto/RICallo might be more beneficial than CR with auto/auto (the gain is 7% in both arms for CR achieved at 9 months, and larger with RICallo for later CR), but this is not shown in Figure 4d .
DISCUSSION
The beneficial effect of CR in patients with multiple myeloma has been reported in several studies; [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] however, there is limited information on the actual impact in allogeneic as compared with autologous HSCT. 12 In the present analysis of the EBMT-NMAM2000 study, we compared for the first time directly and prospectively the impact of CR achievement in autologous and allogeneic treatment protocols. We confirmed previous findings that obtaining CR is important for both PFS and OS; [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] in addition, by using appropriate methodology, we investigated the change of effect according to the stage of treatment when CR is achieved and the type of second HSCT. CR after the first HSCT and before the second is of major importance irrespective of transplant modality. Furthermore, we could also show that for PFS, the impact of CR after second transplant was greater when occurring after auto/RICallo than after auto/auto as assessed from the models and curves for PFS, indicating that the quality of the remission was better with auto/RICallo. The combined effect of higher CR rates and higher protection against progression/relapse when CR is achieved after RICallo turned into significantly higher probabilities of surviving in first CR, as shown both in the analysis from study entry and according to administration of second HSCT.
The prognostic factors at diagnosis and at first HSCT were well balanced as shown in our previous report. 13 The better outcome with CR after auto/RICallo does not seem to result solely from more intensive conditioning treatment. The auto/RICallo procedure used the same conditioning-Melphalan 200 mg/m 2 -for auto as in the auto or auto/auto procedures, and conditioning for RICallo was non-myeloablative, using 200cGy TBI in combination with CYA and mycophenolate mofetil. Thus, the graft-vs-myeloma effect 24, 25 may play a role not only in increasing the CR rate, but also in improving the quality and the duration of the CR resulting in prolonged CR and PFS. Likewise, previous studies have shown that molecular remission is more often obtained with allogeneic than with autologous transplantation 26 and molecular remission is more important for sustained CR than a hematologic remission. 27, 28 In the present multicentre study, the EBMT criteria 18 were used and, for practical reasons, it was not possible to further analyze the quality of CR, that is, with molecular methods. For OS, the investigations are limited in power by a reduced number of events compared to PFS. An even longer follow-up than the current one is probably necessary to observe a potential higher benefit of CR for OS with auto/RICallo.
Previous assessments of outcome probabilities related to response were hampered by the use of inappropriate or inefficient statistical methodology. In the present study, we used both traditional Cox regression and the novel methodology of multistate models. [15] [16] [17] As compared with Cox regression, where the effects are expressed as hazard ratios, in multi-state models, the differences between groups defined by the occurrence or not of an event (CR) during the follow-up are measured in terms of actual probability of the endpoint of interest. A large HR might turn into a small difference of the real risk of failure, depending on the baseline risk; thus, hazard ratios are not exhaustive measures of impact. Actual probabilities are more relevant for predictions and more meaningful for clinicians and patients than hazard functions, and they can be displayed in informative graphs. With adequate sample size, differences between curves with confidence intervals can be computed and tested for significance at specific time points as we showed.
Multi-state models allow assessments of total combined effects of various elements of the disease history in one endpoint, as compared with the traditional methods where all components are analyzed separately. In the present study, we could analyze the probability of surviving in first CR (Figures 2 and 3) , a new endpoint dependent upon the hazard of achievement of CR and the hazard of relapse and death. This is a simplified version of the curve known in the framework of allogeneic HSCT for CML as current leukemia-free survival 29, 30 also obtained by a multi-state approach.
Finally, the results of a multi-state analysis can be presented in the form of a dynamic prediction (Figure 4 ), useful to show the impact of events occurring during the course of the disease on the probability of specific outcomes. In this analysis, we illustrated the effect of CR achievement, in another study we used a threestate multi-state model to investigate the impact of second autologous HSCT and its timing in multiple myeloma. 31 The multi-state methodology has significantly higher potential than standard methods and should be considered in the future when investigating time-to-event outcomes in the presence of one or more intermediate events.
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